What is Thymosin Alpha-1?
Thymosin Alpha-1 (Ta1) is the N-terminal fragment of prothymosin alpha, naturally secreted by thymic epithelial cells. It is one of the most studied immunomodulatory peptides, with approved clinical use in several countries (Zadaxin) for hepatitis B, hepatitis C, and as an adjunct in chemotherapy-associated immunosuppression. Research has examined its ability to restore immune competence in immunocompromised individuals, enhance vaccine responses, and exert antitumor activity via immune stimulation.
Mechanism of action
Thymosin Alpha-1 acts on dendritic cells and T-cell progenitors via Toll-like receptor 9 (TLR9) and other innate immune pattern-recognition receptors. It promotes differentiation of naive T cells into Th1 effectors, enhances natural killer cell activity, upregulates MHC class I and II expression, and increases interferon-alpha/gamma production. The net result is enhanced adaptive immunity without promoting inflammatory autoimmune responses.
Researched benefits
- Enhanced T-cell function and Th1 immune polarization in immunocompromised models
- Antiviral activity demonstrated in hepatitis B and C clinical trials (approved in 35+ countries)
- Improved vaccine immunogenicity when used as an adjuvant in elderly populations
- Reduction in infection rates in critically ill and post-surgical patient studies
- NK cell activity enhancement and anti-tumor immune signaling in oncology research
Researched dosage
Most research protocols use 900–1800 mcg administered 1× per day via subcutaneous injection. Clinical studies have used 900 mcg (0.9 mg) to 1800 mcg (1.8 mg) subcutaneously 2–3 times per week. The approved Zadaxin dose is 1.6 mg twice weekly for 6 months in hepatitis B protocols.
A typical cycle runs 26 weeks on, then 8 weeks off before reassessment.
Use the calculator below to convert your target Thymosin Alpha-1 dose into exact insulin-syringe units.
Reconstitution & storage
A standard 1.5 mg vial reconstituted with 1 mL of bacteriostatic water yields 1500 mcg/mL. Lyophilized vials stable at 2–8°C. Refrigerate reconstituted solution and use within 8 hours per manufacturer guidance; some research protocols allow up to 24 hours.
Side effects & considerations
- Mild injection-site reactions (erythema, discomfort) in some subjects
- Transient flu-like symptoms reported early in treatment protocols
- Potential immune overstimulation concern in autoimmune conditions (theoretical)
Thymosin Alpha-1 stacks
- Immune Restoration Protocol — paired with BPC-157. Immune modulation combined with gut-barrier and systemic healing support. Researchers have explored Thymosin Alpha-1 with BPC-157 in models of immunosuppression accompanied by gut-barrier compromise, as BPC-157's mucosal healing may support immune system inputs from the gut-associated lymphoid tissue.
- Cognitive & Immune Dual Protocol — paired with Selank. Overlapping immunostimulatory and anxiolytic-immune pathways. Both Selank and Thymosin Alpha-1 engage innate immune mechanisms. Some researchers study this pairing for combined immune support and cognitive-stress reduction.
Selected research
- Thymalfasin for hepatitis B: a systematic review — Expert Opinion on Biological Therapy, 2005
- Thymosin alpha 1 as an immunomodulatory agent in sepsis — Critical Care Medicine, 2011
- Thymosin alpha-1 in COVID-19 critically ill patients: a randomized clinical trial — European Journal of Internal Medicine, 2021